Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Wang
Institutions:
Beijing University of Chinese Medicine,
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Observed institutions:
Hebei Medical University,
Beijing University of Chinese Medicine,
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,
First Affiliated Hospital of Hebei Medical University
ORCID:
0000-0002-8671-1959
Observed ORCID:
0000-0002-8671-1959
OpenAlex ID:
A5059506931
JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism
2025
·
Wenying Qi
, Xu Cao
, et al.
·
Phytomedicine
·
28
Research Progress of Chinese Medicine in the Regulation of Liver Fibrosis-Related Signaling Pathways
2024
·
Shihao Zheng
, Chengyuan Xue
, et al.
·
The American Journal of Chinese Medicine
·
11
Immune cells in metabolic associated fatty liver disease: Global trends and hotspots (2004-2024)
2025
·
Wen-Ying Qi
, Shi-Hao Zheng
, et al.
·
World Journal of Hepatology
·
7
PDF
Research Progress of Chinese Medicine in Treating Chronic Liver Disease by Regulating Autophagy
2024
·
Shihao Zheng
, Chengyuan Xue
, et al.
·
The American Journal of Chinese Medicine
·
6
The Chinese Herbal TiaoGanXiaoZhi Formula Alleviates the Progression of Metabolic‐Associated Fatty Liver Disease by Regulating the Gut Microbiota
2025
·
Wenying Qi
, Xu Cao
, et al.
·
Portal hypertension & cirrhosis
·
2
PDF
Exploring the Molecular Mechanism of Niuxi-Mugua Formula in Treating Coronavirus Disease 2019 via Network Pharmacology, Computational Biology, and Surface Plasmon Resonance Verification
2023
·
Wei Wang
, Xu Cao
, et al.
·
Current Computer - Aided Drug Design
Retraction Note: LncRNA TLR8-AS1 suppresses miR-34a maturation in hepatocellular carcinoma to suppress cell proliferation and migration
2023
·
Xin Shi
, Hu Chen
, et al.
·
Mammalian Genome
PDF
Show more works
View as search
Works count:
7
Citation count:
54
H-index:
4
I10-index:
2
Year
Topic
Type